Project Grant SB1AT011593
Award Date
9/19/24
Completion Date
8/31/26
Dollars Obligated
$400K
Funding Federal Agency
National Institute of Neurological Disorders and Stroke
Awarding Federal Agency
National Center for Complementary and Integrative Health
Awardee
2Morrow Inc. (ZS1JSAKF9FK7)
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Kirkland, WA 98034, USA
Similar Awards
This SBIR Phase II award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $2,776,138 to Neurocarrus Inc. to develop a novel biologic drug called N-001 for the management of acute nociceptive pain. The funding will be used to optimize the production and formulation of N-001, establish manufacturing standards and controls, and conduct pivotal preclinical studies to demonstrate the safety and...
This Cooperative Agreement award, totaling $3,075,096.00, was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279). The primary objectives are to develop and validate a digital biosignature monitoring system to assess chronic musculoskeletal (MSK) pain experience in youth aged 14-24. The project will combine physiological, sleep, and physical activity data from wearable devices with artificial...
This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on developing novel methods for selectively stimulating nociceptors (pain receptors) and measuring the brain's nociceptive-specific response in both healthy individuals and those with the chronic pain condition fibromyalgia. The $2,314,276 award to Emory University will fund the creation of a new...
This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $444,125 in funding to Duke University to explore the role of the LRRC55 regulatory protein in pain pathways. The key objectives are to: 1) delineate LRRC55's function in chronic pain behaviors using genetically-modified mice, 2) quantify changes in LRRC55 expression in dorsal root ganglion and spinal cord neurons...
This Project Grant award of $431,643, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports the development and pilot testing of a telehealth-delivered, pain-targeted motivational smoking intervention for smokers with chronic pain who are not ready to quit. The project aims to adapt an existing in-person intervention to a telehealth format and evaluate its feasibility and acceptability in a pilot randomized controlled...
The Project Grant award R61NS133704, totaling $1,846,202.00, was provided by the National Institute of Neurological Disorders and Stroke under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to Duke University. The primary objective is to develop potent, selective, and peripherally-restricted antagonists of the adrenergic receptor beta-3 (ADRB3) for the treatment of chronic primary pain conditions affecting over 100 million people. This will involve: 1) developing novel ADRB3...
This Cooperative Agreement awarded by the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $4,451,386 in funding to the University of Washington to adapt, pilot, and implement a Nurse Care Management (NCM) model for rural patients with chronic pain. The NCM model includes care coordination, cognitive behavioral therapy, and referrals to a remotely delivered exercise program. The project aims to enhance...
This federal Project Grant award in the amount of $351,097 was provided by the National Institute of Neurological Disorders and Stroke (NINDS), which is part of the National Institutes of Health (NIH). The grant was awarded under the NIH's Drug Use and Addiction Research Programs (CFDA 93.279) to establish a rigorous and supportive interdisciplinary training program in clinical pain research at Mass General Brigham (MGB) in Boston. The program will support a diverse pool of 8 postdoctoral...
This $2,249,392 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to validate senescent cells as a target for the treatment of chronic pain in aging. The project aims to rigorously characterize the role of senescent neurons and their senescence-associated secretory phenotype (SASP) in driving dorsal root ganglion hyperexcitability and persistent pain following...